AdaptiveCME: Advances in Treatment to Improve the Quality of Life for Patients with Moderate-to-Severe Atopic DermatitisSpecial Considerations healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Dupilumab was associated with improved clinical, safety and quality of life parameters in older patients with moderate to severe atopic dermatitis, according to findings from a post-hoc analysis of four studies.In the analysis published in the American Journal of Clinical Dermatology, Jonathan I. Silverberg, MD, of The George Washington University School of Medicine and Health Sciences, and
Two phase 3 trials found that lebrikizumab was effective against moderate-to-severe atopic dermatitis in adolescents and adults, researchers reported in The New England Journal of Medicine.